Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Non-Current Liabilities (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Other Non-Current Liabilities for 11 consecutive years, with $27.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 328.08% to $27.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $27.3 million, a 328.08% increase, with the full-year FY2025 number at $4.9 million, down 61.41% from a year prior.
  • Other Non-Current Liabilities was $27.3 million for Q4 2025 at Aytu Biopharma, up from $20.4 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $27.3 million in Q4 2025 to a low of $319000.0 in Q3 2021.
  • A 5-year average of $9.2 million and a median of $7.9 million in 2023 define the central range for Other Non-Current Liabilities.
  • Biggest YoY gain for Other Non-Current Liabilities was 167918.18% in 2021; the steepest drop was 97.56% in 2021.
  • Aytu Biopharma's Other Non-Current Liabilities stood at $8.3 million in 2021, then plummeted by 49.92% to $4.2 million in 2022, then skyrocketed by 210.16% to $12.9 million in 2023, then plummeted by 50.45% to $6.4 million in 2024, then soared by 328.08% to $27.3 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Other Non-Current Liabilities are $27.3 million (Q4 2025), $20.4 million (Q3 2025), and $4.9 million (Q2 2025).